| (Values in U.S. Thousands) | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 |
| Sales | 29,500 | 3,600 | 3,660 | 250,730 | 44,670 |
| Sales Growth | +719.44% | -1.64% | -98.54% | +461.29% | -18.16% |
| Net Income | -211,910 | -266,580 | -819,380 | -618,700 | -789,610 |
| Net Income Growth | +20.51% | +67.47% | -32.44% | +21.64% | -42.11% |
Bluebird Bio (BLUE)
3.84 +0.05 (+1.32%) 10:48 ET [NASDAQ]
3.80 x 204 3.82 x 5
Realtime by (Cboe BZX)
3.80 x 204 3.82 x 5
Realtime 3.70 -0.09 (-2.35%) 09:16 ET
for Fri, Mar 28th, 2025
bluebird bio, Inc. is a clinical-stage biotechnology that is focused on developing gene therapies for severe genetic diseases and cancer. The company has developed a deep pipeline using lentiviral-based gene therapies, T-cell immunotherapy expertise, and gene editing capabilities to treat severe genetic diseases as well as cancer.'The pipeline for severe genetic diseases includes betibeglogene autotemcel (beti-cel) for the treatment of transfusion-dependent '-thalassemia (TDT).
Fiscal Year End Date: 12/31